Abstract 15054: Impact of Sarcoidosis-Related Admission in Patients With Heart Failure: A Nationwide Readmissions Database Analysis (2017-2020)

Abstract

Background: Sarcoidosis is an infiltrative systemic disorder that commonly involves the heart. Despite a higher prevalence of herat failure (HF) among patients with cardiac sarcoidosis (CS), data on these patients’ outcomes remain scarce. Objective: This study aimed to assess the impact of concomitant CS in patients admitted for HF on in-hospital outcomes and 30-day readmission rates. Methods: Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged 18 years or older who were admitted with a primary diagnosis of HF between 2017 and 2020. We stratified the cohort into two groups depending on the presence of sarcoidosis diagnosis. The in-hospital outcomes of both groups were assessed with weighted propensity score matching and multivariable analyses. Results: Our analysis included 1,902,068 patients with a primary diagnosis of HF, whereby 9,343 (0.49%) patients had sarcoidosis. Via multivariable analysis, sarcoidosis was associated with an increased risk of prolonged hospital stays (aOR: 1.15 [95% CI: 1.08 - 1.23], p<0.01), 30-day readmission (aOR: 1.18 [95% CI: 1.11 - 1.25], p=0.01), and higher cumulative cost of hospitalization ($16,179 vs $13,421, p<0.01) among HF cohort. Sarcoidosis was not associated with an increased risk of early mortality. Among HF patients with sarcoidosis, the most common cause of 30-day readmission was cardiovascular causes (59%), where decompensated HF accounted for 50% of the readmission, followed by ischemic heart disease (2%), valvular heart disease (1%), and pulmonary embolism (1%). Conclusion: In conclusion, our study suggests that HF patients with sarcoidosis had poorer in-hospital outcomes with prolonged hospital stays, higher 30-day readmission rates, and increased cumulative hospitalization costs. These findings merit increased effort in the early diagnosis and treatment of CS to improve outcomes in HF patients with sarcoidosis.